Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Here, the baseline and emergent resistance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) versus efavirenz (EFV)/FTC/TDF in HIV-1-infected antiretroviral-naive adults through 144 weeks from the randomized, ongoing, Phase III study GS-US-236-0102 is described.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Antivir. Ther. (Lond.)

Title: Antiviral therapy

Publisher: International Medical Press

ISSN (Electronic): 2040-2058

ISSN (Print): 1359-6535

Publication date (Electronic): 2015

Volume: 20

Issue: 3

Affiliations

[1 ] Clinical Virology, Gilead Sciences, Inc., Foster City, CA, USA. Kirsten.White@gilead.com.

Article

DOI: 10.3851/IMP2885

PubMed ID: 25321623

SO-VID: 17a0fb05-834b-436e-92ad-cf5de5f06cc9

History

Data availability:

Comments

Comment on this article

scite_

Cited by 4

See all cited by